Advances in Epigenetics of Chondrosarcoma
10.3870/j.issn.1672-0741.22.06.019
- VernacularTitle:软骨肉瘤的表观遗传学研究进展
- Author:
Chao LI
1
;
Feifei PU
;
Jianxiang LIU
Author Information
1. 华中科技大学同济医学院附属协和医院骨科,武汉 430022
- Keywords:
chondrosarcoma;
epigenetics;
DNA methylation;
non-coding RNA;
histone modification
- From:
Acta Medicinae Universitatis Scientiae et Technologiae Huazhong
2024;53(3):399-402,413
- CountryChina
- Language:Chinese
-
Abstract:
Chondrosarcoma(CHS)is the second most common primary bone malignancy in human.Recurrence and metasta-sis are common among patients,and the efficacies of radiotherapy and chemotherapy are limited.The development of CHS treat-ment method has stagnated in the past 30-40 years,and surgical treatment is still the dominant option.Research on the patho-genesis mechanism of CHS is still not clear,and there is no specific drug.Therefore,it is of great significance to explore the pathogenesis of CHS,so as to find new treatment methods and drug targets for clinical treatment.Some studies have shown that epigenetic factor play an important role in the pathogenesis of CHS.Epigenetics refers to changes in the expression level and function of a gene without the change in its DNA sequence,leading to a heritable phenotype.The mechanisms of epigenetics mainly include DNA methylation,non-coding RNA regulation,histone modification,and chromatin remodeling.In this review,the recent progress in the field of epigenetics in CHS is summarized,which provides a direction for further research on CHS and searching for new therapeutic targets.
